Skip to main content

Table 1 Characteristics of the included studies

From: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

Study (reference no.)YearStudy design (NCT No.)InterventionsSex (male/female),Age (mean ± SD)Baseline Migraine-days per month (mean ± SD)Follow-up
Uwe Reuter [14]2018RCT phase3b, NCT03096834erenumab 140 mg
Placebo
24/97,44.6 ± 10.5
22/103,44.2 ± 10.6
9.2 ± 2.6
9.3 ± 2.7
12w
David W Dodick [15]2017RCT phase 3, NCT02483585erenumab 70 mg
Placebo
41/245,42 ± 11
44/247,42 ± 12
8.1 ± 2.7
8.4 ± 2.6
12w
Peter J. Goadsby [24]2017RCT phase 3, NCT02456740erenumab 70 mg
Placebo
49/268,41.1 ± 11.3
45/274,41.3 ± 11.2
8.3 ± 2.5
8.2 ± 2.5
24w
Hong Sun [25]2016RCT phase 2, NCT01952574erenumab 70 mg
Placebo
25/82, 42.6 ± 9.9
28/132,41.4 ± 10.0
8.6 ± 2.5
8.8 ± 2.7
12w
David W Dodick [26]2014RCT phase 2, NCT01772524Eptinezumab 1000 mg
Placebo
14/67,38.6 ± 10.8
16/66,39.0 ± 9.6
8.4 ± 2.1
8.8 ± 2.7
12w
David W. Dodick [16]2018RCT phase 3, NCT02629861Fremanezumab 225 mg
Placebo
46/244,42.9 ± 12.7
47/247, 41.3 ± 12.0
8.9 ± 2.6
9.1 ± 2.7
12w
Marcelo E Bigal [27]2015RCT phase 2b, NCT02025556Fremanezumab 225 mg
Placebo
9/87,40.8 ± 12.4
12/92,42.0 ± 11.6
11.5 ± 1.9
11.5 ± 2.24
12w
Vladimir Skljarevski# [28]2018RCT phase 2b, NCT02163993Galcanezumab 120 mg
Placebo
42/231,40.6 ± 11.9
28/109,39.5 ± 12.1
6.7 ± 2.6
6.6 ± 2.7
12w
Vladimir Skljarevski [18]2017RCT Phase 3, NCT02614196galcanezumab 120 mg
Placebo
34/197,40.9 ± 11.2
68/393,42.3 ± 11.3
9.07 ± 2.9
9.2 ± 3.0
24w
Virginia L. Stauffer [17]2018RCT phase 3, NCT02614183galcanezumab 120 mg
Placebo
32/181,40.9 ± 11.9
71/362,41.3 ± 11.4
9.2 ± 3.1
9.1 ± 3.0
24w
David W Dodick [29]2014RCT phase 2, NCT01625988galcanezumab 150 mg
Placebo
19/88,40.9 ± 11.4
14/96,41.9 ± 11.7
6.7 ± 2.4
7.0 ± 2.5
12w
  1. RCT Randomized controlled trial, SD Standard deviation. #The specific information can only be achieved in the total CGRP monoclonal antibodies treatment group